Clinical Trial Update: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the first-line combination of orelabrutinib with obinutuzumab and lenalidomide (OGL regimen) for marginal zone lymphoma and is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING